CLINICAL TRIAL

NCT03328130

Retinal RED

Interventional

Phase 1/2

Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression

Rare Eye Disease concerned by the trial :
Retinitis Pigmentosa

Status of the trial : recruiting

Orphan drug recognition : Yes

Inclusion criteria : age ≥ 18 years ; clinical and molecular diagnosis of retinitis pigmentosa caused by defect in PDE6B gene without other syndromic manifestations

Exclusion criteria : click here to see detailed criteria

Inclusion opening date : 06/11/2017

Inclusion closing date (previsional) : 30/06/2020

Children ☐

Adults ☑

Within ERN-EYE members

Principal location of the trial :

Clinique Ophtalmologique
CHU de Nantes
1 place Alexis-Ricordeau
44093 Nantes Cedex 1

Principal investigator name :
Dr Pierre Lebranchu

Other investigators :
Dr Isabelle Meunier

Maolya - National Rare Disease center
CHU Gui de Chauliac
80, avenue Augustin Fliche
34 295 Montpellier Cedex 5

Contact details



Funder type : Drug company - Industry

More informations